Publication

Article

CURE

Summer 2007
Volume6
Issue 4

www.re-mission.net

Author(s):

Elizabeth Whittington

Gamers take virtual shot at cancer.

Teens and young adults fighting cancer can now really battle the disease with Re-Mission, a video game that pits a robot called Roxxi against cancer cells and bacterial infections, while dealing with side effects at a microscopic level within the bodies of fictional patients. HopeLab, a nonprofit focused on children with chronic illnesses, developed the video game with game developers, animators, psychologists, and scientists. Re-Mission is available free at www.re-mission.net. The website also offers an online community for teens and young adults with cancer.

Articles in this issue
How to Find Help
Job Transitions, Insurance Change
Medicare Coverage for Colon Cancer Screenings
Noting Group Differences
The Journey of Cancer Survivorship
Beauty Shopping
Pregnancy After Cancer
Fast Facts: Richard Roundtree
Portal Authority
Precious Tumor
Surviving "Survivor" Stereotypes
The Secret of Caregivers
Surgeons and Robots
A Hole In The World
Making the Most of a Portal

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Image of two doctors and text.
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma
Image of man.
Image of Dr. Evens.
Image of carly.
Image of kelly.
Image of doctor.
Image of Dr. Kelly
image of doctor D'Sa
Related Content
Mark Daniels, 83, says CAR T-cell therapy and strong support helped him overcome lymphoma twice.
July 2nd 2025

Veteran Credits CAR T-Cell Therapy With Helping Him Reach Remission

Spencer Feldman
Mark Daniels, 83, says CAR T-cell therapy and strong support helped him overcome lymphoma twice and return to the fitness-focused life he values.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
The FDA grants priority review to Revuforj’s supplemental new drug application to treat R/R mNPM1 AML: © stock.adobe.com.
June 26th 2025

FDA Grants Priority Review to Revuforj for Mutant NPM1 AML

Spencer Feldman
The FDA has granted priority review to an application for Revuforj for the treatment of relapsed or refractory mutant NPM1 acute myeloid leukemia.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Image of kidney
June 19th 2025

Why is Clinical Trial Enrollment Important for Those With Kidney Cancer?

Ryan Scott
Dr. Michael Serzan explains the importance of clinical trial enrollment for patients with kidney cancer and highlighted findings from the STELLA-002 trial.
The FDA approved Monjuvi with Revlimid and Rituxan for R/R follicular lymphoma: © stock.adobe.com.
June 18th 2025

FDA Approves Monjuvi With Revlimid and Rituxan for Follicular Lymphoma

Spencer Feldman
The FDA approved Monjuvi with Revlimid and Rituxan for R/R follicular lymphoma after it showed significantly longer progression-free survival vs placebo.